A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated follicular non-Hodgkin?s lymphoma.

Trial Profile

A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated follicular non-Hodgkin?s lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Rituximab (Primary) ; Antineoplastics
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 19 Sep 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
    • 07 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top